Gardasil®

BIOLOGICAL5 trials

Sponsors

Shanghai Bovax Biotechnology Co., Ltd., PATH, Sinocelltech Ltd.

Conditions

AISCIN1CIN2CIN3Cervical CancerGenital WartHPV Infection Vaccine Safety SCT1000Interventional

Phase 1

A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years

Sinocelltech Ltd.HPV Infection Vaccine Safety SCT1000

Start: 2021-07-02End: 2022-10-31Target: 240Updated: 2021-09-17

Phase 2

A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 Years

Sinocelltech Ltd.Interventional, Prevention, Randomized

Start: 2021-10-19End: 2022-07-31Target: 1800Updated: 2021-10-28

Phase 3

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

RecruitingNCT04422366

Shanghai Bovax Biotechnology Co., Ltd.AIS, Cervical Cancer, CIN1 +11

Start: 2020-04-28End: 2029-09-15Target: 8000Updated: 2024-06-07

Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

CompletedNCT04425291

Shanghai Bovax Biotechnology Co., Ltd.AIS, Cervical Cancer, CIN1 +11

Start: 2020-05-28End: 2021-09-06Updated: 2022-02-25

Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls

CompletedNCT04508309

PATHCervical Cancer

Start: 2021-03-15End: 2023-12-14Updated: 2025-01-30

Related Papers

Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9-14 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trial.

2025-03-193 citations